ClinicalTrials.gg
RecruitingNCT07149870TEAMWORKUpdated Aug 17, 2026

Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial

An interventional study of Pain Management Team + Whole Health Coach (PMT-WHC) and Pain Management Team-Usual Care (PMT-UC) in Chronic Pain, sponsored by VA Office of Research and Development. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Chronic Pain by VA Office of Research and Development — 14 open to participants now, 15 under way, none of them phase 3. Chronic Pain · VA Office of Research and Development.

Planned enrollment
2nd of 53
432 · median 126
Started
2025
with 3 others
No phase
44 of 57
10 open now
Primary completion
2029-10
later than 12 of 14 live
Registered
54th of 57
by date

Among the 57 studies in Chronic Pain by VA Office of Research and Development, this one is the 2nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 44 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 54th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 57 studies in Chronic Pain by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Chronic Pain by VA Office of Research and Development, or all of them as a file.
02

Study summary

The focus of this study is to determine whether adding Whole Health Coaching (WHC) improves pain care among adults with chronic pain and who are currently working with a pain management team (PMT) at the VA.

Read the detailed description

This multisite pragmatic effectiveness-implementation hybrid type 2 trial will randomize 432 patients to compare Pain Management Team - Usual Care (PMT-UC) vs. Pain Management Team Usual Care + Whole Health Coaching (PMT-WHC) on the primary composite outcome of pain-related interference and opioid safety. The investigators will also evaluate the impact of PMT-WHC on buprenorphine initiation and maintenance, evaluate implementation facilitation strategies for building and sustaining PMTs, and conduct a budget impact analysis.

The primary study goal is to evaluate the effectiveness of adding Whole Health Coaching to PMTs adhering to VA standards on the primary composite outcome of pain-related function and opioid safety, and secondary outcomes of wellbeing and physical functioning. Participants will have a 50/50 random chance of being assigned to (a) continuing to receive usual care from the PMT or (b) receiving WHC in addition to the usual care provided by the PMT.

Both groups will receive usual care from the PMT, which will include a baseline evaluation with at least two PMT clinicians. Follow-up appointments will vary based on clinical judgment of the PMT members, but most patients will be followed for at least six months with at least three follow-up appointments. Both groups will complete questionnaires via telephone at (1) baseline, (2) month 1, (3) month 3, (4) month 6, and (5) month 12. The questionnaires will ask about personal characteristics and demographics, pain, physical function, ability to do activities, social support, sleep, mental health, use of medications and health services, and substance use.

If assigned to participate in PMT-WHC, participants will work with a Whole Health Coach for a minimum of eight (8) individual sessions, with the option to continue coaching for up to 12 individual sessions. Whole Health Coaching begins by completing a Personalized Health Inventory (PHI), where progress is assessed within eight (8) dimensions of health and wellness: Physical, Emotional, Social, Spiritual, Intellectual, Environmental, Financial, and Occupational health. The Inventory culminates in defining personal values and overall goals for health and wellness (i.e., "What do you want your health for?") based on a person's mission, aspiration, and purpose. This will be used to create goals that become part of a Personal Health Plan. The Personal Health Plan emphasizes self-management strategies to manage pain. After the Plan is developed, ongoing support is provided from the Coach in coaching sessions. Coaches will meet with participants on a biweekly basis for the first three (3) months after randomization and on a monthly basis for the final two (2) months, for a minimum total of eight (8) sessions across approximately five (5) months. The sessions with the WHC will be recorded (audio recordings only, no photographs or video recordings). However, participation is still available in this study if participants decline to be recorded.

Participants may also be selected to participate in a qualitative interview. If selected, the interview covers participant experiences and opinions about working with the PMT, and, if relevant, the WHC. This interview will be recorded and will be approximately 60 minutes. Participants are not required to complete the interview and are still eligible to participate in this research study if the interview portion is declined.

The study will also evaluate implementation facilitation as a strategy to support PMTs in implementing care for patients with pain and opioid safety concerns. Implementation facilitation will include audit and feedback and other strategies tailored to each site. A budget impact analysis will monitor implementation and intervention costs.

03

Conditions studied

  • Chronic Pain

Keywords

  • Opioid Use
  • Opioid Safety
  • Pain
  • Chronic Pain
  • Long-term Opioid Therapy
  • Pain Management
  • Opioid
  • Whole Health
  • Coaching
  • Whole Health Coaching
  • Pain, Chronic
  • Buprenorphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. High-impact chronic pain (defined using the Graded Chronic Pain Scale - Revised).
  2. Active prescription for long-term opioid therapy (LTOT; including full agonist and buprenorphine) (>90 days continuous prescription).
  3. Exhibit evidence of at least ONE opioid safety concern (*indicators of opioid safety concerns described below).

    • Opioid safety concerns for inclusion purposes include:

      1. moderate-to-high dose opioid prescription (morphine equivalent daily dose >60mg)
      2. comorbid conditions that increase the risk of full-agonist opioids including chronic pulmonary disease (e.g., emphysema, chronic bronchitis, asthma, or other breathing problems), sleep apnea, chronic kidney disease, chronic hepatitis or cirrhosis
      3. active high-risk co-prescriptions, including long-term benzodiazepine prescription, gabapentin or pregabalin, nonbenzodiazepine hypnotic agents or sedative hypnotics, or skeletal muscle relaxants
      4. a positive TAPS or AUDIT-C score
      5. reported score of >8 as measured by the Prescribed Opioids Difficulties Scale (PODS).

Exclusion criteria

Exclusion Criteria:

  1. Moderate to severe cognitive impairment as measured by the Blessed Orientation Memory Concentration (BOMC) screening tool.
  2. Inability to read or understand English.
  3. Severely impaired hearing or speech that would preclude participation in telephone interviews or appointments with the Whole Health Coach.
  4. Terminal illness/disease with a prognosis of \<12 months.
  5. Planned move/relocation outside of the treatment areas of the participating enrolling study sites.
  6. Participants actively working with a Whole Health Coach or who have worked with a Whole Health Coach in the 6-months prior to enrollment.
  7. Major surgical procedure planned during the study treatment or follow-up period.
  8. a recent suicide attempt, defined as documented and/or reported suicide attempt within 90 days of the screening date.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
432 participants (estimated)

Study arms

  • Experimental
    PMT-WHC

    The PMT-WHC group will receive PMT Usual Care plus 8 sessions of Whole Health Coaching (WHC)

    Other: Pain Management Team + Whole Health Coach (PMT-WHC) · Other: Pain Management Team-Usual Care (PMT-UC)

  • Active comparator
    PMT-UC

    The PMT-UC group will receive PMT Usual Care

    Other: Pain Management Team-Usual Care (PMT-UC)

Interventions

  • OtherPain Management Team + Whole Health Coach (PMT-WHC)

    Whole Health Coaching (WHC) begins by completing a Personalized Health Inventory (PHI), where progress is evaluated within 8 dimensions of health and wellness. The PHI culminates in defining personal values and overall goals for health and wellness (i.e., "What do you want your health for?"). This is used to create goals for a Personal Health Plan. The Plan emphasizes self-management strategies to manage pain. After the Plan is developed, ongoing support is provided from the Coach through 8-12 coaching sessions over approximately 5 months.

    Also known as: PMT-WHC

  • OtherPain Management Team-Usual Care (PMT-UC)

    Pain Management Team-Usual Care (PMT-UC) involves working with VA PMTs that includes working with PMTs comply with legislation requiring each medical center to have PMTs with expertise in pain, addiction, behavioral approaches, and rehabilitation approaches. PMTs will conduct multidisciplinary intakes (at least two provider types) with biopsychosocial assessments for all new patients. Follow-up care will be determined by the PMTs based on what is clinically indicated (with recommended minimum medication management follow ups at 1- 3- and 6-months for patients making medication changes).

    Also known as: PMT-UC

06

What researchers measure

Primary outcomes

  1. Composite of Pain Interference and Opioid Safety

    The primary outcome is a composite of pain-related interference and opioid safety. Success is met when pain-related interference and opioid safety improve. The pain component of the primary outcome is change in pain interference from baseline, measured on the Brief Pain Inventory, categorized as improved/not improved; where improvement: ≥1 point reduction in pain-related interference. The opioid safety component is defined as success in ≥1 of the following: (1) initiating and continuing buprenorphine for ≥ 90 days, (2) evidence of opioid taper ( \>25% reduction in daily full agonist opioid dose, including opioid discontinuation), (3) \>25% reduction in dose of benzodiazepine, gabapentin, pregabalin, nonbenzodiazepine hypnotic agents/sedative hypnotics, or skeletal muscle relaxant, (4) resolution of a positive baseline TAPS-2 score, (5) resolution of a positive AUDIT-C score, or (6) reduction in opioid-related difficulties as measured by the Prescribed Opioids Difficulties scale.

    Time frame: 6 months

Secondary outcomes

  1. Opioid Safety

    The investigators will evaluate improved opioid safety as a secondary outcome, whereby success (binary yes/no) is improvement in any of the following: 1. initiating and continuing buprenorphine for at least 90 days 2. evidence of an opioid taper (i.e., a \>25% reduction in daily full agonist opioid dose, including opioid discontinuation), measured at the 6-month follow-up visit 3. \>25% reduction in dose of benzodiazepine, gabapentin, pregabalin, nonbenzodiazepine hypnotic agents or sedative hypnotics, or skeletal muscle relaxant 4. resolution of a positive baseline TAPS-2 score, 5. resolution of a positive AUDIT-C score, or 6. reduction in opioid-related difficulties as measured by the Prescribed Opioids Difficulties (PODS) scale.

    Time frame: 6 months, 12 months

  2. Well-Being Signs (WBS) Tool

    The Wellbeing Signs Tool is a three (3) item screening tool with items asking respondents to rate how well they are doing in their daily lives; higher scores indicated better wellbeing and life satisfaction.

    Time frame: 6 months, 12 months

  3. Pain Interference - Brief Pain Inventory (BPI)- Interference scale

    The pain component of the composite primary outcome, measured at 6-month and 12-month follow-up, will be change in pain interference from baseline, measured on the Brief Pain Inventory - Interference scale, using 11-point scales ranging from 0 (no pan interference) to 10 (complete pain interference), with higher scores indicating a greater degree to which pain is disrupting quality of life, and categorized as improved/not improved with improvement defined as a ≥1 point reduction in pain-related interference.

    Time frame: 6 months, 12 months

  4. Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Functioning Short Form 6b

    Physical Functioning: An assessment of the impact of pain on several aspects of functioning, including social and emotional processes as well as physical function (e.g., how much did pain interfere with your day to day activities).

    Time frame: 6 months, 12 months

  5. Composite of Pain Interference and Opioid Safety

    We will examine the composite of pain-related interference and opioid safety (primary outcome at 6 mo) as a secondary outcome for durability of effects at 12 mo. The pain component of the primary outcome is change in pain interference from baseline, measured on the Brief Pain Inventory, categorized as improved/not improved; where improvement: ≥1 point reduction in pain-related interference. The opioid safety component is defined as success in ≥1 of the following: (1) initiating and continuing buprenorphine for ≥ 90 days, (2) evidence of opioid taper (\>25% reduction in daily full agonist opioid dose, including opioid discontinuation), (3) \>25% reduction in dose of benzodiazepine, gabapentin, pregabalin, nonbenzodiazepine hypnotic agents/sedative hypnotics, or skeletal muscle relaxant, (4) resolution of a positive baseline TAPS-2 score, (5) resolution of a positive AUDIT-C score, or (6) reduction in opioid-related difficulties as measured by the Prescribed Opioids Difficulties scale.

    Time frame: 12 months

Other outcomes

  1. World Health Organization - Quality of Life (WHOQOL- 2)

    The WHOQOL assesses individuals' perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. The 2-item version of this measure (recommended by the NIH HEAL CDE Initiative) will be used.

    Time frame: 6 months, 12 months

  2. Patients' Global Impression of Change (PGIC)

    Global Satisfaction with Treatment: A scale for respondents to rate the level of change experienced following treatment. The PGIC is a 7-point scale from 1 (very much better) to 7 (very much worse).

    Time frame: 6 months, 12 months

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2029, 46 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 46 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Sep 2, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07149870
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Nov 20, 2025
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Aug 17, 2026

Study contacts

Danielle M Wesolowicz, PhD
Contact
Danielle.Wesolowicz@va.gov
(203) 932-5711
Deanna J Ternes, BS
Contact
deanna.ternes@va.gov
(971) 404-1473
Sara Edmond, PhD
principal investigator · VA Connecticut Healthcare System West Haven Campus, West Haven, CT
Karen H Seal, MD MPH
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion